Skip to main content
SpringerLink
Log in

Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Heparin compounds, to include fractionated and unfractionated preparations, exert both antithrombotic and antiinflammatory effects through combined inhibition of factor Xa and thrombin. The contribution of modulated platelet activity in vivo is less clearly defined. The SYNERGY library was a prospectively designed repository for candidate clinical, hemostatic, platelet, and molecular biomarkers from patients participating in SYNERGY—a large-scale, randomized clinical trial evaluating the comparative benefits of unfractionated heparin (UFH) and enoxaparin in high-risk patients with acute coronary syndrome (ACS). Samples were collected from 201 patients enrolled at 26 experienced, participating sites and shipped to established core laboratories for analysis of platelet, endothelium-derived, inflammatory and coagulation activity biomarkers. Tissue factor pathway inhibitor (TFPI)—a vascular endothelial cell-derived factor Xa regulatory protein—correlated directly with plasma anti-Xa activity (unadjusted: r = 0.23, P < 0.0001; adjusted: β = 0.10; P = 0.001), as did TFPI–fXa complexes (unadjusted: r = 0.34, P < 0.0001; adjusted: β = 0.38; P = < 0.0001). In contrast, there was a direct and inverse relationship between anti-Xa activity and two platelet-derived biomarkers—plasminogen activator inhibitor-1 (unadjusted: r = −0.18, P = 0.0012; adjusted: β = −0.10; P = 0.021) and soluble CD40 ligand (unadjusted: r = −0.11, P = 0.05; adjusted: β = −0.13; P = 0.049). All measured analyte relationships persisted after adjustment for age, creatinine clearance, weight, sex, and duration of treatment. Differences in biomarkers between patients receiving UFH and those randomized to enoxaparin were not observed. The ability of heparin compounds to affect the prothrombotic and proinflammatory states which characterize ACS may involve factor Xa-related modulation of platelet activation and expression. Whether this potentially beneficial effect is direct or indirect and achieved, at least in part, through the release of endothelial cell-derived coagulation regulatory proteins will require further investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Koenig W, Khuseyinova N (2007) Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 27(1):15–26

    Article  CAS  PubMed  Google Scholar 

  2. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105(9):1135–1143

    Article  CAS  PubMed  Google Scholar 

  3. Namba M et al (2007) Circulating platelet-derived microparticles are associated with atherothrombotic events: a marker for vulnerable blood. Arterioscler Thromb Vasc Biol 27(1):255–256

    Article  CAS  PubMed  Google Scholar 

  4. Waxman S, Ishibashi F, Muller JE (2006) Detection and treatment of vulnerable plaques and vulnerable patients: novel approaches to prevention of coronary events. Circulation 114(22):2390–2411

    Article  PubMed  Google Scholar 

  5. Petersen JL et al (2004) Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library. Am Heart J 148:269–276

    Article  CAS  PubMed  Google Scholar 

  6. Ferguson JJ et al (2004) Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. J Am Med Assoc 292(1):45–54

    Article  CAS  Google Scholar 

  7. Falk E (2006) Pathogenesis of atherosclerosis. J Am Coll Cardiol 47(8 Suppl):C7–C12

    Article  CAS  PubMed  Google Scholar 

  8. Becker RC et al (1996) Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in myocardial ischemia III B investigators. Am Heart J 131(3):421–433

    Article  CAS  PubMed  Google Scholar 

  9. Wagenvoord R et al (2008) Linear diffusion of thrombin and factor Xa along the heparin molecule explains the effects of extended heparin chain lengths. Thromb Res 122(2):237–245

    Article  CAS  PubMed  Google Scholar 

  10. Becker RC et al (2002) Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 143:753–759

    Article  CAS  PubMed  Google Scholar 

  11. Montalescot G et al (2006) Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 355(10):1006–1017

    Article  CAS  PubMed  Google Scholar 

  12. Montalescot G et al (2008) Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial. Eur Heart J 29(4):462–471

    Article  CAS  PubMed  Google Scholar 

  13. Allen GA et al (2004) Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost 2(3):402–413

    Article  CAS  PubMed  Google Scholar 

  14. Kempton CL et al (2005) Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations. Arterioscler Thromb Vasc Biol 25(4):861–866

    Article  CAS  PubMed  Google Scholar 

  15. Cirino G et al (1997) Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo. J Clin Investig 99(10):2446–2451

    Article  CAS  PubMed  Google Scholar 

  16. Daubie V et al (2006) Factor Xa and thrombin evoke additive calcium and proinflammatory responses in endothelial cells subjected to coagulation. Biochim Biophys Acta 1763(8):860–869

    Article  CAS  PubMed  Google Scholar 

  17. Rapaport SI, Rao LV (1992) Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 12(10):1111–1121

    CAS  PubMed  Google Scholar 

  18. Broze GJ Jr (1992) The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 29(3):159–169

    CAS  PubMed  Google Scholar 

  19. Bajaj MS et al (1999) Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues. Thromb Haemost 82(3):1047–1052

    CAS  PubMed  Google Scholar 

  20. Golino P et al (2003) Involvement of tissue factor pathway inhibitor in the coronary circulation of patients with acute coronary syndromes. Circulation 108(23):2864–2869

    Article  CAS  PubMed  Google Scholar 

  21. Li Y et al (2002) Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance. J Thromb Thrombolysis 14(2):123–129

    Article  CAS  PubMed  Google Scholar 

  22. Becker RC et al (2004) Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a–a selective and direct factor Xa inhibitor. J Thromb Thrombolysis 18(3):193–197

    Article  CAS  PubMed  Google Scholar 

  23. Henn V et al (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391(6667):591–594

    Article  CAS  PubMed  Google Scholar 

  24. Michelson AD et al (2001) Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 104(13):1533–1537

    Article  CAS  PubMed  Google Scholar 

  25. Furman MI et al (2001) Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 38(4):1002–1006

    Article  CAS  PubMed  Google Scholar 

  26. Nakamura R et al (2006) Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin. Thromb Haemost 95(4):637–642

    CAS  PubMed  Google Scholar 

  27. Bianchini EP, Pike RN, Le Bonniec BF (2004) The elusive role of the potential factor X cation-binding exosite-1 in substrate and inhibitor interactions. J Biol Chem 279(5):3671–3679

    Article  CAS  PubMed  Google Scholar 

  28. Becker RC et al (1994) The clinical use of flow cytometry for assessing platelet activation in acute coronary syndromes. TIMI-III thrombosis and anticoagulation group. Coron Artery Dis 5(4):339–345

    Article  CAS  PubMed  Google Scholar 

  29. Brogren H et al (2004) Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood 104(13):3943–3948

    Article  CAS  PubMed  Google Scholar 

  30. Montalescot G et al (2003) Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Am J Cardiol 91(8):925–930

    Article  CAS  PubMed  Google Scholar 

  31. Montalescot G et al (2000) Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 36(1):110–114

    Article  CAS  PubMed  Google Scholar 

  32. Jayachandran M (2005) Estrogenic regulation of tissue factor and tissue factor pathway inhibitor in platelets. Am J Physiol Heart Circ Physiol 289(5):H1908–H1916

    Article  CAS  PubMed  Google Scholar 

  33. Xiao Z, Theroux P (1998) Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 97(3):251–256

    CAS  PubMed  Google Scholar 

  34. Landolfi R et al (1994) Effects of unfractionated and low molecular weight heparins on platelet thromboxane biosynthesis “in vivo”. Thromb Haemost 72(6):942–946

    CAS  PubMed  Google Scholar 

  35. Miletich JP, Jackson CM, Majerus PW (1977) Interaction of coagulation factor Xa with human platelets. Proc Natl Acad Sci USA 74(9):4033–4036

    Article  CAS  PubMed  Google Scholar 

  36. Heiden D, Mielke CH Jr, Rodvien R Jr (1977) Impairment by heparin of primary haemostasis and platelet [14C]5-hydroxytryptamine release. Br J Haematol 36(3):427–436

    Article  CAS  PubMed  Google Scholar 

  37. Fernandez F et al (1986) Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 43(4):491–495

    Article  CAS  PubMed  Google Scholar 

  38. De Candia E, De Cristofaro R, Landolfi R (1999) Thrombin-induced platelet activation is inhibited by high- and low-molecular-weight heparin. Circulation 99(25):3308–3314

    PubMed  Google Scholar 

  39. Heeschen C et al (2003) Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348(12):1104–1111

    Article  CAS  PubMed  Google Scholar 

  40. Konishi N, Hiroe K, Kawamura M (2010) Synergistic effect of a factor Xa inhibitor, TAK-442, and antiplatelet agents on whole blood coagulation and arterial thrombosis in rats. Thrombo Res 126(2):124–129

    Article  CAS  Google Scholar 

  41. Samama MM et al (2010) Assessment of laboratory assays to measure rivaroxaban–an oral, direct factor Xa inhibitor. Thromb Haemost 103(4):815–825

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Shaun G. Goodman, MD, Gregg W. Stone, MD, Alexandra J. Lansky, MD, Marc Cohen, MD, Robert M. Califf, MD, and James J. Ferguson, MD, the site principal investigators and coordinators who participated in the SYNERGY library and Amanda McMillan for her editorial assistance.

Funding

Funded by sanofi-aventis.

Author information

Authors and Affiliations

  1. Division of Cardiology Medicine, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, 27715, USA

    Richard C. Becker, Kenneth W. Mahaffey & Craig J. Reist

  2. Duke Cardiovascular Thrombosis Center, Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC, 27715, USA

    Richard C. Becker & Hongqiu Yang

  3. Division of Cardiology, Baylor College of Medicine, Houston, TX, USA

    A. J. Marian & Neal S. Kleiman

  4. Division of Cardiology, South Shore Hospital, South Weymouth, MA, USA

    Mark I. Furman

  5. Department of Cardiology, Cleveland Clinic Foundation, Cleveland, OH, USA

    A. Michael Lincoff & Stanley L. Hazen

  6. Department of Cardiology, Swedish Heart & Vascular Clinic, Seattle, WA, USA

    John L. Petersen

Authors
  1. Richard C. Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth W. Mahaffey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hongqiu Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. J. Marian
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mark I. Furman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Michael Lincoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Stanley L. Hazen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. John L. Petersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Craig J. Reist
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Neal S. Kleiman
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

SYNERGY Investigators

Corresponding author

Correspondence to Richard C. Becker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Becker, R.C., Mahaffey, K.W., Yang, H. et al. Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome. J Thromb Thrombolysis 31, 146–153 (2011). https://doi.org/10.1007/s11239-010-0532-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-010-0532-y

Keywords

Search

Navigation